Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NZT1

UPID:
CALL5_HUMAN

ALTERNATIVE NAMES:
Calmodulin-like skin protein

ALTERNATIVE UPACC:
Q9NZT1; Q5SQI3; Q8IXU8

BACKGROUND:
The Calmodulin-like protein 5, alternatively known as Calmodulin-like skin protein, is integral to calcium binding, a critical process in the terminal differentiation of keratinocytes. This differentiation is vital for the development and maintenance of the skin's protective barrier. The protein's unique interaction with calcium ions underscores its importance in skin health and cellular function.

THERAPEUTIC SIGNIFICANCE:
Investigating Calmodulin-like protein 5's function offers a pathway to novel therapeutic approaches. Given its key role in skin cell differentiation, this protein could be central to developing new treatments for dermatological conditions, promoting skin health, and advancing wound repair. The potential for therapeutic innovation in understanding this protein's mechanisms is vast.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.